New eye drops aim to soothe Sjogren's dry eye sufferers

NCT ID NCT05136170

Completed Symptom relief Sponsor: Dompé Farmaceutici S.p.A Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 study tested cenegermin (Oxervate) eye drops against a placebo in 85 adults with severe dry eye caused by Sjogren's syndrome, who were already using cyclosporine drops. The goal was to see if cenegermin could increase tear production and reduce eye discomfort over 4 weeks of treatment, with follow-up for several months. The trial is now complete, and results will show whether this nerve growth factor treatment offers extra relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cenegermin (recombinant human Nerve Growth Factor) eye drops
What this could lead to: If it works, this could provide a new treatment option for people with severe dry eye from Sjogren's disease, improving tear production and comfort.
What could go wrong: This is a relatively small Phase 3 trial (85 people) and results may not apply to everyone. The treatment is added on top of existing therapy, so benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE DISEASE

Contacts and locations

Locations

AOU Gaspare Rodolico - Ospedale San Marco

Catania, 95123, Italy
AOU Policlinico Umberto I - Dipartimento Organi di Senso - Clinica Oculistica

Roma, 00161, Italy
Houston Eye Associates HEA - Gramercy Location

Houston, Tennessee, 77025, United States
Lugene Eye Institute - Glendale Office

Glendale, California, 91204, United States
OCLI (Ophthalmic Consultants of Long Island)

Garden City, New York, 11530, United States
Scheie Eye Institute

Philadelphia, Pennsylvania, 19104, United States
The Johns Hopkins University

Baltimore, Maryland, 21218, United States
Toyos Clinic - Nashville

Nashville, Tennessee, 37215, United States
Tufts University School of Medicine (TUSM) - New England Eye Center/Tufts Medical Center

Boston, Massachusetts, 02111, United States
Università degli Studi di Milano - Ospedale San Giuseppe - UO Oculistica

Milan, 20123, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.